Company Description

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.

The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.

The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.

Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Nuvectis Pharma, Inc.

Country	United States
Founded	2020
IPO Date	Feb 4, 2022
Industry	Biotechnology
Sector	Healthcare
Employees	13
CEO	Ron Bentsur

Contact Details

Address: 1 Bridge Plaza, 2nd Floor, Suite 275 Fort Lee, New Jersey 07024 United States
Phone	201 614 3150
Website	nuvectis.com

Stock Details

Ticker Symbol	NVCT
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$5.00
CIK Code	1875558
CUSIP Number	67080T108
ISIN Number	US67080T1088
Employer ID	86-2405608
SIC Code	2834

Key Executives

Name	Position
Ron Bentsur M.B.A.	Co-Founder, Chairman, Chief Executive Officer and President
Dr. Enrique Poradosu Ph.D.	Co-Founder, Executive Vice President, Chief Scientific and Business Officer
Shay Shemesh	Co-Founder, Executive Vice President, Chief Development and Operations Officer

Latest SEC Filings

Date	Type	Title
Feb 20, 2026	EFFECT	Notice of Effectiveness
Feb 13, 2026	S-3	Registration statement under Securities Act of 1933
Feb 11, 2026	8-K	Current Report
Feb 11, 2026	10-K	Annual Report
Nov 4, 2025	8-K	Current Report
Nov 4, 2025	10-Q	Quarterly Report
Sep 25, 2025	8-K	Current Report
Aug 5, 2025	10-Q	Quarterly Report
Aug 5, 2025	8-K	Current Report
Jun 13, 2025	8-K	Current Report

View All SEC Filings